Metadata Standard and Data Exchange Specifications to Describe, Model, and Integrate Complex and Diverse High-Throughput Screening Data from the Library of Integrated Network-based Cellular Signatures (LINCS)

The National Institutes of Health Library of Integrated Network-based Cellular Signatures (LINCS) program is generating extensive multidimensional data sets, including biochemical, genome-wide transcriptional, and phenotypic cellular response signatures to a variety of small-molecule and genetic perturbations with the goal of creating a sustainable, widely applicable, and readily accessible systems biology knowledge resource. Integration and analysis of diverse LINCS data sets depend on the availability of sufficient metadata to describe the assays and screening results and on their syntactic, structural, and semantic consistency. Here we report metadata specifications for the most important molecular and cellular components and recommend them for adoption beyond the LINCS project. We focus on the minimum required information to model LINCS assays and results based on a number of use cases, and we recommend controlled terminologies and ontologies to annotate assays with syntactic consistency and semantic integrity. We also report specifications for a simple annotation format (SAF) to describe assays and screening results based on our metadata specifications with explicit controlled vocabularies. SAF specifically serves to programmatically access and exchange LINCS data as a prerequisite for a distributed information management infrastructure. We applied the metadata specifications to annotate large numbers of LINCS cell lines, proteins, and small molecules. The resources generated and presented here are freely available.

[1]  Cathy H. Wu,et al.  Community annotation in biology , 2010, Biology Direct.

[2]  Brian D Athey,et al.  The Cell Line Ontology and its use in tagging cell line names in biomedical text. , 2007, AMIA ... Annual Symposium proceedings. AMIA Symposium.

[3]  Péter Lénárt,et al.  BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo , 2007, Current Biology.

[4]  Henning Hermjakob,et al.  Minimum information about a protein affinity reagent (MIAPAR) , 2010, Nature Biotechnology.

[5]  Susanna-Assunta Sansone,et al.  Empowering industrial research with shared biomedical vocabularies. , 2011, Drug discovery today.

[6]  Ubbo Visser,et al.  BioAssay Ontology (BAO): a semantic description of bioassays and high-throughput screening results , 2011, BMC Bioinformatics.

[7]  Colin J. Ihrig.  JavaScript Object Notation , 2013 .

[8]  Birgit Gaschler-Markefski,et al.  The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed, Chemotherapy: Results from an Open-Label, Randomized Phase II Clinical Trial , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  Nigel W. Hardy,et al.  Promoting coherent minimum reporting guidelines for biological and biomedical investigations: the MIBBI project , 2008, Nature Biotechnology.

[10]  C E Lipscomb,et al.  Medical Subject Headings (MeSH). , 2000, Bulletin of the Medical Library Association.

[11]  Stephan C Schürer,et al.  BioAssay Ontology Annotations Facilitate Cross-Analysis of Diverse High-Throughput Screening Data Sets , 2011, Journal of biomolecular screening.

[12]  Alexander D. Diehl,et al.  Logical Development of the Cell Ontology , 2011, BMC Bioinformatics.

[13]  Helge Weissig,et al.  Functional interrogation of the kinome using nucleotide acyl phosphates. , 2007, Biochemistry.

[14]  Gang Feng,et al.  From disease ontology to disease-ontology lite: statistical methods to adapt a general-purpose ontology for the test of gene-ontology associations , 2009, Bioinform..

[15]  S A Forbes,et al.  The Catalogue of Somatic Mutations in Cancer (COSMIC) , 2008, Current protocols in human genetics.

[16]  Martin Renqiang Min,et al.  An integrated encyclopedia of DNA elements in the human genome , 2012 .

[17]  L. Wodicka,et al.  A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.

[18]  R. Kaiser,et al.  Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours. , 2012, Current oncology.

[19]  Robert Stevens,et al.  Gene Ontology Consortium , 2014 .

[20]  S. Lewis,et al.  Uberon, an integrative multi-species anatomy ontology , 2012, Genome Biology.

[21]  Jessica A. Turner,et al.  Modeling biomedical experimental processes with OBI , 2010, J. Biomed. Semant..

[22]  Sitta Sittampalam,et al.  Open access high throughput drug discovery in the public domain: a Mount Everest in the making. , 2010, Current pharmaceutical biotechnology.

[23]  Anne E. Trefethen,et al.  Toward interoperable bioscience data , 2012, Nature Genetics.

[24]  Caroline Shamu,et al.  Differential Determinants of Cancer Cell Insensitivity to Antimitotic Drugs Discriminated by a One-Step Cell Imaging Assay , 2013, Journal of biomolecular screening.

[25]  Ubbo Visser,et al.  Formalization, Annotation and Analysis of Diverse Drug and Probe Screening Assay Datasets Using the BioAssay Ontology (BAO) , 2012, PloS one.

[26]  Raymond K. Auerbach,et al.  An Integrated Encyclopedia of DNA Elements in the Human Genome , 2012, Nature.

[27]  Peter Murray-Rust,et al.  Minimum information about a bioactive entity (MIABE) , 2011, Nature Reviews Drug Discovery.

[28]  T. Golub,et al.  A method for high-throughput gene expression signature analysis , 2006, Genome Biology.

[29]  Asha Collins.  The Cancer Genome Atlas (TCGA) Pilot Project , 2007 .

[30]  Data production leads,et al.  An integrated encyclopedia of DNA elements in the human genome , 2012 .